Annual report
4937.TEDINET S100XCAJ
Period2024-10-01 → 2025-09-30
Filed2025-12-23
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 132
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.0bn | 2024-10-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥1.9bn | 2023-10-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥1.7bn | 2022-10-01 → 2023-09-30v | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.7bn | 2021-10-01 → 2022-09-30v | Cons. | Net sales (5-year summary) |
| Operating income | ¥151m | 2024-10-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥56m | 2023-10-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥152m | 2024-10-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥57m | 2023-10-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥288m | 2022-10-01 → 2023-09-30v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥22m | 2021-10-01 → 2022-09-30v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥152m | 2024-10-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥57m | 2023-10-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥44m | 2024-10-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥17m | 2023-10-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥28m | 2022-10-01 → 2023-09-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥57m | 2021-10-01 → 2022-09-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥44m | 2024-10-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | −¥17m | 2023-10-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥3.2bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥3.1bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥1.6bn | at 2023-09-30v | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.6bn | at 2022-09-30v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.1bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥993m | at 2024-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥2.1bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥2.1bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥773m | at 2023-09-30v | Cons. | Net assets |
| Net assets / equity | ¥743m | at 2022-09-30v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.3bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.5bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.3bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.5bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2023-09-30v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥906m | at 2022-09-30v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥136m | 2024-10-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥49m | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥456m | 2022-10-01 → 2023-09-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥169m | 2021-10-01 → 2022-09-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥189m | 2024-10-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥76m | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥49m | 2022-10-01 → 2023-09-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥176m | 2021-10-01 → 2022-09-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥150m | 2024-10-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥112m | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥8m | 2022-10-01 → 2023-09-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥129m | 2021-10-01 → 2022-09-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥12.32 | 2024-10-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.03 | 2023-10-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥9.43 | 2022-10-01 → 2023-09-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-19.04 | 2021-10-01 → 2022-09-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥12.24 | 2024-10-01 → 2025-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥9.32 | 2022-10-01 → 2023-09-30v | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥591.15 | at 2025-09-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥590.33 | at 2024-09-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥256.73 | at 2023-09-30v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥246.98 | at 2022-09-30v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 65.1% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.2% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.9% | at 2023-09-30v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.5% | at 2022-09-30v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 2.1% | 2024-10-01 → 2025-09-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.7% | 2022-10-01 → 2023-09-30v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 93 | at 2025-09-30 | Cons. | Number of employees |
| Employees | 86 | at 2024-09-30 | Cons. | Number of employees |
| Employees | 50 | at 2023-09-30v | Cons. | Number of employees |
| Employees | 44 | at 2022-09-30v | Cons. | Number of employees |
| Revenue | ¥1.3bn | 2024-10-01 → 2025-09-30 | Standalone | Net sales |
| Revenue | ¥1.6bn | 2023-10-01 → 2024-09-30 | Standalone | Net sales |
| Revenue | ¥1.7bn | 2022-10-01 → 2023-09-30v | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.7bn | 2021-10-01 → 2022-09-30v | Standalone | Net sales (5-year summary) |
| Revenue | ¥4.7bn | 2020-10-01 → 2021-09-30d | Standalone | Net sales (5-year summary) |
| Operating income | −¥76m | 2024-10-01 → 2025-09-30 | Standalone | Operating income |
| Operating income | −¥54m | 2023-10-01 → 2024-09-30 | Standalone | Operating income |
| Ordinary income | −¥43m | 2024-10-01 → 2025-09-30 | Standalone | Ordinary income |
| Ordinary income | −¥28m | 2023-10-01 → 2024-09-30 | Standalone | Ordinary income |
| Ordinary income | ¥275m | 2022-10-01 → 2023-09-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥21m | 2021-10-01 → 2022-09-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥141m | 2020-10-01 → 2021-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥43m | 2024-10-01 → 2025-09-30 | Standalone | Income before income taxes |
| Profit before tax | −¥28m | 2023-10-01 → 2024-09-30 | Standalone | Income before income taxes |
| Net income | −¥45m | 2024-10-01 → 2025-09-30 | Standalone | Profit loss |
| Net income | −¥30m | 2023-10-01 → 2024-09-30 | Standalone | Profit loss |
| Net income | ¥32m | 2022-10-01 → 2023-09-30v | Standalone | Net income loss (5-year summary) |
| Net income | −¥57m | 2021-10-01 → 2022-09-30v | Standalone | Net income loss (5-year summary) |
| Net income | ¥116m | 2020-10-01 → 2021-09-30d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥2.7bn | at 2025-09-30 | Standalone | Assets |
| Total assets | ¥2.9bn | at 2024-09-30 | Standalone | Assets |
| Total assets | ¥1.6bn | at 2023-09-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.6bn | at 2022-09-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.9bn | at 2021-09-30d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥711m | at 2025-09-30 | Standalone | Liabilities |
| Total liabilities | ¥810m | at 2024-09-30 | Standalone | Liabilities |
| Net assets / equity | ¥2.0bn | at 2025-09-30 | Standalone | Net assets |
| Net assets / equity | ¥2.1bn | at 2024-09-30 | Standalone | Net assets |
| Net assets / equity | ¥777m | at 2023-09-30v | Standalone | Net assets |
| Net assets / equity | ¥743m | at 2022-09-30v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥801m | at 2021-09-30d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥976m | at 2025-09-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.2bn | at 2024-09-30 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.0bn | at 2021-09-30d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥128m | 2020-10-01 → 2021-09-30d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥6m | 2020-10-01 → 2021-09-30d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥703m | 2020-10-01 → 2021-09-30d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-12.56 | 2024-10-01 → 2025-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.77 | 2023-10-01 → 2024-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥10.57 | 2022-10-01 → 2023-09-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-18.95 | 2021-10-01 → 2022-09-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥41.61 | 2020-10-01 → 2021-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥10.44 | 2022-10-01 → 2023-09-30v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥40.9 | 2020-10-01 → 2021-09-30d | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥563.24 | at 2025-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥587.77 | at 2024-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥257.96 | at 2023-09-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥247.07 | at 2022-09-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥266.72 | at 2021-09-30d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 73.4% | at 2025-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.3% | at 2024-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.2% | at 2023-09-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.5% | at 2022-09-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.1% | at 2021-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 4.2% | 2022-10-01 → 2023-09-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 24.1% | 2020-10-01 → 2021-09-30d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 3,622,668 | at 2025-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,618,928 | at 2024-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,010,278 | at 2023-09-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,006,178 | at 2022-09-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,001,178 | at 2021-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 61 | at 2025-09-30 | Standalone | Number of employees |
| Employees | 60 | at 2024-09-30 | Standalone | Number of employees |
| Employees | 50 | at 2023-09-30v | Standalone | Number of employees |
| Employees | 44 | at 2022-09-30v | Standalone | Number of employees |
| Employees | 72 | at 2021-09-30d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 48
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-10-01 → 2025-09-30 | ¥5m |
| Reconciling Itemsreconciling | depreciation | 2024-10-01 → 2025-09-30 | ¥682,000 |
| Reconciling Itemsreconciling | revenue | 2024-10-01 → 2025-09-30 | ¥9m |
| Reconciling Itemsreconciling | revenue external | 2024-10-01 → 2025-09-30 | ¥9m |
| Reconciling Itemsreconciling | segment profit | 2024-10-01 → 2025-09-30 | −¥28m |
| Direct To Consumer Businessreportable segment | revenue | 2024-10-01 → 2025-09-30 | ¥953m |
| Direct To Consumer Businessreportable segment | revenue external | 2024-10-01 → 2025-09-30 | ¥953m |
| Direct To Consumer Businessreportable segment | segment profit | 2024-10-01 → 2025-09-30 | ¥295m |
| Medical Supportreportable segment | revenue | 2024-10-01 → 2025-09-30 | ¥1.0bn |
| Medical Supportreportable segment | revenue external | 2024-10-01 → 2025-09-30 | ¥999m |
| Medical Supportreportable segment | revenue intersegment | 2024-10-01 → 2025-09-30 | ¥1m |
| Medical Supportreportable segment | segment profit | 2024-10-01 → 2025-09-30 | ¥216m |
| —segment total | capex | 2024-10-01 → 2025-09-30 | ¥262m |
| —segment total | depreciation | 2024-10-01 → 2025-09-30 | ¥13m |
| —segment total | revenue | 2024-10-01 → 2025-09-30 | ¥2.0bn |
| —segment total | revenue external | 2024-10-01 → 2025-09-30 | ¥2.0bn |
| —segment total | revenue intersegment | 2024-10-01 → 2025-09-30 | ¥1m |
| —segment total | segment profit | 2024-10-01 → 2025-09-30 | ¥511m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-10-01 → 2025-09-30 | ¥262m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-10-01 → 2025-09-30 | ¥13m |
| Reconciling Itemsreconciling | capex | 2023-10-01 → 2024-09-30 | ¥322,000 |
| Reconciling Itemsreconciling | depreciation | 2023-10-01 → 2024-09-30 | ¥745,000 |
| Reconciling Itemsreconciling | revenue | 2023-10-01 → 2024-09-30 | −¥2m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-10-01 → 2024-09-30 | −¥2m |
| Reconciling Itemsreconciling | segment profit | 2023-10-01 → 2024-09-30 | −¥393m |
| Direct To Consumer Businessreportable segment | depreciation | 2023-10-01 → 2024-09-30 | ¥5m |
| Direct To Consumer Businessreportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥1.3bn |
| Direct To Consumer Businessreportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥1.3bn |
| Direct To Consumer Businessreportable segment | revenue intersegment | 2023-10-01 → 2024-09-30 | ¥75,000 |
| Direct To Consumer Businessreportable segment | segment profit | 2023-10-01 → 2024-09-30 | ¥386m |
| Medical Supportreportable segment | capex | 2023-10-01 → 2024-09-30 | ¥80m |
| Medical Supportreportable segment | depreciation | 2023-10-01 → 2024-09-30 | ¥8m |
| Medical Supportreportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥629m |
| Medical Supportreportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥627m |
| Medical Supportreportable segment | revenue intersegment | 2023-10-01 → 2024-09-30 | ¥2m |
| Medical Supportreportable segment | segment profit | 2023-10-01 → 2024-09-30 | ¥64m |
| —segment total | capex | 2023-10-01 → 2024-09-30 | ¥80m |
| —segment total | depreciation | 2023-10-01 → 2024-09-30 | ¥12m |
| —segment total | revenue | 2023-10-01 → 2024-09-30 | ¥1.9bn |
| —segment total | revenue external | 2023-10-01 → 2024-09-30 | ¥1.9bn |
| —segment total | revenue intersegment | 2023-10-01 → 2024-09-30 | ¥2m |
| —segment total | segment profit | 2023-10-01 → 2024-09-30 | ¥450m |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-10-01 → 2024-09-30 | ¥80m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-10-01 → 2024-09-30 | ¥12m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-10-01 → 2024-09-30 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-10-01 → 2024-09-30 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-10-01 → 2024-09-30 | ¥2m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-10-01 → 2024-09-30 | ¥450m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,221
| Item | Context | Value | Unit |
|---|---|---|---|
| Consolidated statement of changes in equity (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies for preparation of consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Number of consolidated subsidiaries and names of major consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Number of unconsolidated subsidiaries and associates accounted for using equity method and names of major entities accounted for using equity method (text) | CurrentYearDuration | Text · Plus | |
| Disclosure about fiscal years etc of consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Disclosure of accounting policies (text) | CurrentYearDuration | Text · Plus | |
| Significant accounting estimates consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes new accounting standards not yet applied consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Debtors notes regarding overdraft contracts and or loan commitments (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding amount of revenue from contracts with customers (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding write downs of inventories (text) | CurrentYearDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYearDuration | Text · Plus | |
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period (text) | CurrentYearDuration | Text · Plus | |
| Notes consolidated statement of comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding new share subscription rights etc (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding new share subscription rights etc (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYearDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Description of significant transactions not requiring use of cash or cash equivalents (text) | CurrentYearDuration | Text · Plus | |
| Notes leases consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes financial instruments consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes retirement benefits consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes share options etc consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes tax effect accounting consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes asset retirement obligations consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes revenue recognition consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes segment information etc consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Description of reportable segments (text) | CurrentYearDuration | Text · Plus | |
| Explanation of measurements of sales profit loss asset liability and other items for each reportable segment (text) | CurrentYearDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YearDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYearDuration | Text · Plus | |
| Information for each product or service (text) | Prior1YearDuration | Text · Plus | |
| Revenues from external customers information for each region (text) | Prior1YearDuration | Text · Plus | |
| Property plant and equipment information for each region (text) | Prior1YearDuration | Text · Plus | |
| Information for each of main customers (text) | Prior1YearDuration | Text · Plus | |
| Information for each product or service (text) | CurrentYearDuration | Text · Plus | |
| Revenues from external customers information for each region (text) | CurrentYearDuration | Text · Plus | |
| Property plant and equipment information for each region (text) | CurrentYearDuration | Text · Plus | |
| Information for each of main customers (text) | CurrentYearDuration | Text · Plus | |
| Notes related parties consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes per share information consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes significant events after reporting period consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Annexed consolidated detailed schedule of corporate bonds (text) | CurrentYearDuration | Text · Plus | |
| Annexed consolidated detailed schedule of borrowings (text) | CurrentYearDuration | Text · Plus | |
| Annexed consolidated detailed schedule of asset retirement obligations (text) | CurrentYearDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |